182 related articles for article (PubMed ID: 34282568)
1. Human Systemic Immune Response to Ingestion of the Oral Probiotic Streptococcus salivarius BLIS K12.
Laws GL; Hale JDF; Kemp RA
Probiotics Antimicrob Proteins; 2021 Dec; 13(6):1521-1529. PubMed ID: 34282568
[TBL] [Abstract][Full Text] [Related]
2. Interferon Gamma Response in Human Saliva Following Exposure to the Oral Probiotic Streptococcus salivarius BLIS K12.
Laws GA; Harold LK; Tagg JR; Hale JDF
Probiotics Antimicrob Proteins; 2024 Feb; 16(1):93-98. PubMed ID: 36477439
[TBL] [Abstract][Full Text] [Related]
3. In vitro Inhibition of Clinical Isolates of Otitis Media Pathogens by the Probiotic Streptococcus salivarius BLIS K12.
Chen TY; Hale JDF; Tagg JR; Jain R; Voss AL; Mills N; Best EJ; Stevenson DS; Bird PA; Walls T
Probiotics Antimicrob Proteins; 2021 Jun; 13(3):734-738. PubMed ID: 33179212
[TBL] [Abstract][Full Text] [Related]
4. Influence of Oral Probiotic Streptococcus salivarius K12 on Ear and Oral Cavity Health in Humans: Systematic Review.
Zupancic K; Kriksic V; Kovacevic I; Kovacevic D
Probiotics Antimicrob Proteins; 2017 Jun; 9(2):102-110. PubMed ID: 28236205
[TBL] [Abstract][Full Text] [Related]
5. Extended Safety Data for the Oral Cavity Probiotic Streptococcus salivarius K12.
Burton JP; Chilcott CN; Wescombe PA; Tagg JR
Probiotics Antimicrob Proteins; 2010 Oct; 2(3):135-44. PubMed ID: 26781236
[TBL] [Abstract][Full Text] [Related]
6. Multi-Strain Probiotic Supplementation with a Product Containing Human-Native
Cernioglo K; Kalanetra KM; Meier A; Lewis ZT; Underwood MA; Mills DA; Smilowitz JT
Nutrients; 2021 Dec; 13(12):. PubMed ID: 34959944
[No Abstract] [Full Text] [Related]
7. Streptococcus salivarius inhibits immune activation by periodontal disease pathogens.
MacDonald KW; Chanyi RM; Macklaim JM; Cadieux PA; Reid G; Burton JP
BMC Oral Health; 2021 May; 21(1):245. PubMed ID: 33962608
[TBL] [Abstract][Full Text] [Related]
8. Effect of Probiotic Streptococcus salivarius K12 and M18 Lozenges on the Cariogram Parameters of Patients With High Caries Risk: A Randomised Control Trial.
Poorni S; Nivedhitha MS; Srinivasan M; Balasubramaniam A
Cureus; 2022 Mar; 14(3):e23282. PubMed ID: 35449617
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Efficacy of BLIS-Producing Probiotic K12 for the Prevention of Group A Streptococcus Pharyngitis: a Short Communication.
Di Pierro F
Probiotics Antimicrob Proteins; 2019 Mar; 11(1):332-334. PubMed ID: 29464500
[TBL] [Abstract][Full Text] [Related]
10. Effect of administration of Streptococcus salivarius K12 on the occurrence of streptococcal pharyngo-tonsillitis, scarlet fever and acute otitis media in 3 years old children.
Di Pierro F; Colombo M; Giuliani MG; Danza ML; Basile I; Bollani T; Conti AM; Zanvit A; Rottoli AS
Eur Rev Med Pharmacol Sci; 2016 Nov; 20(21):4601-4606. PubMed ID: 27874935
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of safety and human tolerance of the oral probiotic Streptococcus salivarius K12: a randomized, placebo-controlled, double-blind study.
Burton JP; Cowley S; Simon RR; McKinney J; Wescombe PA; Tagg JR
Food Chem Toxicol; 2011 Sep; 49(9):2356-64. PubMed ID: 21722694
[TBL] [Abstract][Full Text] [Related]
12. Use of
Bertuccioli A; Gervasi M; Annibalini G; Binato B; Perroni F; Rocchi MBL; Sisti D; Amatori S
Front Immunol; 2023; 14():1129060. PubMed ID: 36936914
[TBL] [Abstract][Full Text] [Related]
13. Probiotic
Wang Y; Li J; Zhang H; Zheng X; Wang J; Jia X; Peng X; Xie Q; Zou J; Zheng L; Li J; Zhou X; Xu X
Front Immunol; 2021; 12():684824. PubMed ID: 34149727
[TBL] [Abstract][Full Text] [Related]
14. Oral Probiotics, Streptococcus salivarius K12 and M18, Suppress the Release of Volatile Sulfur Compounds and a Virulent Protease from Oral Bacteria: An In-Vitro Study.
Park JA; Lee GR; Lee JY; Jin BH
Oral Health Prev Dent; 2023 Aug; 21():259-270. PubMed ID: 37724895
[TBL] [Abstract][Full Text] [Related]
15. Positive clinical outcomes derived from using
Di Pierro F; Colombo M; Zanvit A; Rottoli AS
Drug Healthc Patient Saf; 2016; 8():77-81. PubMed ID: 27920580
[TBL] [Abstract][Full Text] [Related]
16. Impact of Streptococcus salivarius K12 on Nasopharyngeal and Saliva Microbiome: A Randomized Controlled Trial.
Sarlin S; Tejesvi MV; Turunen J; Vänni P; Pokka T; Renko M; Tapiainen T
Pediatr Infect Dis J; 2021 May; 40(5):394-402. PubMed ID: 33298762
[TBL] [Abstract][Full Text] [Related]
17. The Effect of Oral Probiotics (Streptococcus Salivarius k12) on the Salivary Level of Secretory Immunoglobulin A, Salivation Rate, and Oral Biofilm: A Pilot Randomized Clinical Trial.
Babina K; Salikhova D; Polyakova M; Svitich O; Samoylikov R; Ahmad El-Abed S; Zaytsev A; Novozhilova N
Nutrients; 2022 Mar; 14(5):. PubMed ID: 35268099
[TBL] [Abstract][Full Text] [Related]
18. Prevention of streptococcal pharyngitis by anti-Streptococcus pyogenes bacteriocin-like inhibitory substances (BLIS) produced by Streptococcus salivarius.
Tagg JR
Indian J Med Res; 2004 May; 119 Suppl():13-6. PubMed ID: 15232154
[TBL] [Abstract][Full Text] [Related]
19. Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes and recurrent acute otitis media.
Di Pierro F; Donato G; Fomia F; Adami T; Careddu D; Cassandro C; Albera R
Int J Gen Med; 2012; 5():991-7. PubMed ID: 23233809
[TBL] [Abstract][Full Text] [Related]
20. Effect of Streptococcus salivarius K12 on the in vitro growth of Candida albicans and its protective effect in an oral candidiasis model.
Ishijima SA; Hayama K; Burton JP; Reid G; Okada M; Matsushita Y; Abe S
Appl Environ Microbiol; 2012 Apr; 78(7):2190-9. PubMed ID: 22267663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
